Review of peptide polyagonists (multi-receptor agonists targeting GLP-1R, GIPR, GCGR, FGF21R, or combinations) as therapeutic candidates for non-alcoholic fatty liver disease (NAFLD/NASH). Covers how dual and triple agonists like retatrutide address hepatic steatosis, inflammation, and fibrosis through coordinated metabolic effects on liver, adipose, and gut. Positions retatrutide as a potential NAFLD therapy alongside its obesity and diabetes indications.
Polyzos, Stergios A; Frühbeck, Gema; Kiortsis, Dimitrios N